Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service cholecystectomy & appendectomy cases in North Dakota: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (255 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 16 | 698 | 20% |
| 2020 | 17 | 636 | 22% |
| 2021 | 13 | 562 | 25% |
| 2022 | 13 | 594 | 29% |
| 2023 | 10 | 497 | 34% |
| 2024 | 6 | 502 | 37% |
| 2025 from claims | – | 554 448–650 | 39% |
| 2026 forecast | – | 566 443–711 | 38% |
| 2027 forecast | – | 568 421–751 | 39% |
| 2028 forecast | – | 569 403–786 | 40% |
| 2029 forecast | – | 571 388–819 | 41% |
| 2030 forecast | – | 572 375–849 | 41% |
The highest-volume laparoscopic cases; identifies every active general surgeon. Professional codes (what the surgeon bills): CPT 47562, 47563, 44970, 47600; the hospital bills MS-DRG 417, 418, 419, 338, 339, 340, 397, 398, 399.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in North Dakota; 5 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 43% inpatient hospital, 57% hospital outpatient.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient |
|---|---|---|
| 2026 · ~570 | ~250 | ~320 |
| 2027 · ~570 | ~250 | ~320 |
| 2028 · ~570 | ~250 | ~320 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: hospital outpatient about 56% (57% in 2025), inpatient hospital about 44% (43% in 2025).
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Illinois | 106 | 4,982−6.5%/yr | −6.5%/yr | 3.7 | 2% | 5,420 in 2030+1.4%/yr |
| Ohio | 70 | 4,777−4.3%/yr | −4.3%/yr | 4.5 | 1% | 5,070 in 2030+1%/yr |
| Michigan | 39 | 3,319−9.3%/yr | −9.3%/yr | 4.1 | 1% | 3,010 in 2030−1.6%/yr |
| Indiana | 69 | 3,309−4.8%/yr | −4.8%/yr | 4.8 | 5% | 3,260 in 2030−0.3%/yr |
| Missouri | 76 | 3,242−6.5%/yr | −6.5%/yr | 5.4 | 2% | 3,240 in 20300%/yr |
| Wisconsin | 20 | 2,445−4.2%/yr | −4.2%/yr | 4.5 | 1% | 2,580 in 2030+0.9%/yr |
| Minnesota | 23 | 1,976−5.3%/yr | −5.3%/yr | 4.5 | 2% | 2,420 in 2030+3.5%/yr |
| Kansas | 50 | 1,841−5.1%/yr | −5.1%/yr | 4.6 | 5% | 1,870 in 2030+0.2%/yr |
| Iowa | 36 | 1,637−4.5%/yr | −4.5%/yr | 3.8 | 4% | 1,650 in 2030+0.2%/yr |
| Nebraska | 33 | 1,242−5.8%/yr | −5.8%/yr | 4.9 | 7% | 1,320 in 2030+1%/yr |
| South Dakota | 11 | 645−6.4%/yr | −6.4%/yr | 5.1 | 0% | 750 in 2030+2.6%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Hernia repair | 7 | 627−1.4%/yr | −1.4%/yr | 6.61.1× | 0% | 580 in 2030−1.4%/yr |
| Colorectal resection | 0 | 196−4.4%/yr | −4.4%/yr | 2.01.1× | 0% | 230 in 2030+2.4%/yr |
Cholecystectomy & appendectomy in every state, and its device makers · Every procedure market in North Dakota · Every state · Compare with Illinois
Johnson & Johnson MedTech leads with 77% of company spending on these surgeons in 2025, +68 pts on 2024.
In 2025, 5 companies reported engagement with North Dakota’s surgeons worth $3,406 in consulting, speaking, meals and travel tied to these products, about $568 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 33 clearances and approvals in the category, 2 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.